Biodexa Pharmaceuticals Statistics Share Statistics Biodexa Pharmaceuticals has 3
shares outstanding. The number of shares has increased by -99.63%
in one year.
Shares Outstanding 3 Shares Change (YoY) -99.63% Shares Change (QoQ) -99.63% Owned by Institutions (%) n/a Shares Floating 35 Failed to Deliver (FTD) Shares 733 FTD / Avg. Volume 1.04%
Short Selling Information The latest short interest is 13.53K, so 2.18% of the outstanding
shares have been sold short.
Short Interest 13.53K Short % of Shares Out 2.18% Short % of Float 2.18% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.35 and the forward
PE ratio is null.
Biodexa Pharmaceuticals's PEG ratio is
0.
PE Ratio -0.35 Forward PE n/a PS Ratio 0 Forward PS 0 PB Ratio 0.24 P/FCF Ratio -0.15 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Biodexa Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.75,
with a Debt / Equity ratio of 0.09.
Current Ratio 1.75 Quick Ratio 1.75 Debt / Equity 0.09 Debt / EBITDA -0.08 Debt / FCF -0.06 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-440.69K Employee Count 13 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -250K Effective Tax Rate 4.18%
Stock Price Statistics The stock price has increased by -87.93% in the
last 52 weeks. The beta is 0.92, so Biodexa Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.92 52-Week Price Change -87.93% 50-Day Moving Average 6.6 200-Day Moving Average 19.11 Relative Strength Index (RSI) 54.71 Average Volume (20 Days) 70,313
Income Statement
Revenue n/a Gross Profit -5.44M Operating Income -9.2M Net Income -5.73M EBITDA -9.08M EBIT -9.2M Earnings Per Share (EPS) -1157000
Full Income Statement Balance Sheet The company has 1.67M in cash and 727K in
debt, giving a net cash position of 942K.
Cash & Cash Equivalents 1.67M Total Debt 727K Net Cash 942K Retained Earnings -150.42M Total Assets 14.78M Working Capital 3.78M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.26M
and capital expenditures -774K, giving a free cash flow of -13.04M.
Operating Cash Flow -12.26M Capital Expenditures -774K Free Cash Flow -13.04M FCF Per Share -210.4
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields BDRX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for BDRX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 31, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Jul 31, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -17.26 Piotroski F-Score 1
